ACT Genomics Statement

ACT Genomics Co., Ltd.(“ACT Genomics”) today announced an update to ACTMonitor® Breast, expanding the assay to a 10-gene panel with the addition of AKT1 and PTEN biomarkers. This enhancementis designed to broaden molecular insights available to clinicians andlaboratories supporting breast cancer monitoring and care.

Delta Electronics Inc. ‘s (“Delta”) board of directors approved aproposal to acquire shareholdings of ACT Genomics Holdings Company Limited (“ACTGenomics”). The transaction will only be complete if certain closing conditions and regulatory approvals are fulfilled.